Anokion Company

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can betranslated to virtually any protein in numerous clinical indications.
Industry: PharmTech
Headquarters: Vaud

Visit Website
Register and Claim Ownership